恶性肿瘤患者的凝血及纤溶异常较常见,其发生率根据肿瘤的类型及程度而异,肿瘤患者中其异常的发生率约50%,而在转移性肿瘤则超过90%。这些异常一般并不引起明显症状,但15%以上患者在临床上有出血及血栓形成。患者在急性阶段后期常有严重的复发性血栓形成,应立即作抗凝治疗。英国推荐作3～4天的短程治疗,北美常用7～10天,一般用口服华法令来治疗。对危险性很高患者主张做持续性肝素皮下注射,使部分凝血激酶时间至少保持在对照值的1.5倍。如可能也应积极治疗恶性肿瘤。 Malignant tumor coagulation and fibrinolytic abnormalities are more common, the incidence varies according to the type and degree of tumor, the incidence of abnormalities in cancer patients is about 50%, while in metastatic tumors is more than 90%. These abnormalities generally do not cause significant symptoms, but more than 15% of patients have clinically bleeding and thrombosis. Patients with severe recurrent thrombosis at the end of the acute phase should be treated with anticoagulation immediately. British recommended for short-term treatment of 3 to 4 days, commonly used in North America 7 to 10 days, the general treatment with oral warfarin. Patients with high risk of advocating for sustained heparin subcutaneous injection, the partial thromboplastin time to maintain at least 1.5 times the control value. If possible, should also actively treat malignant tumors.